Minimum custom amount to enter is AED 2
By donating, you agree to the Privacy Policy and Terms of Service
The medical team has successfully used Casgevy gene therapy to treat a young patient with thalassemia major, marking a significant milestone in the field of gene therapy.
This success story is remarkable because it is the first time this treatment has been applied outside of clinical trials and research. Previously, the patient needed blood transfusions every three weeks to manage his condition, but after receiving the gene therapy, he left the medical city with a full recovery.
The Kingdom is now preparing to expand the use of these cutting-edge treatments to patients with sickle cell anemia and other forms of thalassemia. This move is set to strengthen Saudi Arabia’s position in the global gene therapy landscape.
As Saudi continues to embrace innovative medical technologies, this breakthrough represents not only a major step forward in treating genetic disorders but also a beacon of hope for future patients. The successful application of Casgevy gene therapy demonstrates the Kingdom’s commitment to advancing healthcare and improving lives through cutting-edge science.
Minimum custom amount to enter is AED 2
By donating, you agree to the Privacy Policy and Terms of Service